First Comparison of Amulet and Watchman FLX LAA Closure Devices

$ 8.50 · 4.9 (421) · In stock

Results from the SWISS-APERO Trial reported at TCT 2021 and published simultaneously in Circulation

First Comparison of Amulet and Watchman FLX LAA Closure Devices Found Similar Outcomes

Diagnostic and Interventional Cardiology

Left Atrial Appendage (LAA) Occluders

Boston Scientific Receives FDA Approval for Expanded Labeling of WATCHMAN FLX LAAC Device for Dual Anti-Platelet Therapy as Post-Procedural Medication Option

Left Atrial Appendage (LAA) Occluders

Diagnostic and Interventional Cardiology

Left Atrial Appendage (LAA) Occluders

Structural Heart Occluders

TCT DAIC

Late-Breaking Study Results Reinforce Positive Real-World Outcomes with the WATCHMAN FLX LAAC Device